You are here
The past year has been a groundbreaking one for neurology. Not only have at least three new biomarkers been identified for Alzheimer’s disease, but various molecular imaging agents used to visualize neurodegenerative disorders are now either available or being conveyed toward regulatory approval for clinical use. Parkinson’s research, too, has progressed at an astonishing rate with the spoils being a new method of detection and a therapeutic technique that could potentially leave patients tremor-free for life. Several psychiatric disorders are being seen first-hand by targeting the dopaminergic system of the brain. Neuroendocrine tumor (NET) imaging also is pushing forward with a preliminary nod from the FDA in the form of an orphan drug application for NET management.